Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | Talabostat mesylate |
| Synonyms | |
| Therapy Description |
Talabostat mesylate (BXCL701) is a dipeptidyl peptidase inhibitor that may activate T and NK cells and enhance antitumor immune reaction (J Clin Onco 36, no. 15_suppl (May 20 2018) 3085-3085). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| Talabostat mesylate | BXCL701|PT 100|PT-100 | Talabostat mesylate (BXCL701) is a dipeptidyl peptidase inhibitor that may activate T and NK cells and enhance antitumor immune reaction (J Clin Onco 36, no. 15_suppl (May 20 2018) 3085-3085). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT04123574 | Phase I | Talabostat mesylate | A Pilot Study of BXCL701 in Patients With Pancreatic Cancer | Withdrawn | USA | 0 |
| NCT05703542 | Phase I | Talabostat mesylate | BXCL701 Phase 1 R/R Acute Myeloid Leukemia or Myelodysplastic Syndrome | Recruiting | USA | 0 |